Assembly Biosciences (ASMB) Non-Current Debt (2010 - 2011)
Assembly Biosciences (ASMB) recorded quarterly Non-Current Debt of $1.3 million in Q2 2011, up 3.86% quarter-over-quarter from $1.3 million in Q4 2010.
Assembly Biosciences (ASMB) Non-Current Debt (2010 - 2011) Analysis & Trends
Assembly Biosciences' Non-Current Debt history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2011.
- In Q2 2011, Non-Current Debt changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2011 stood at $1.3 million (changed N/A YoY), while the FY2010 annual figure was $1.3 million, changed N/A from the prior year.
- Non-Current Debt was $1.3 million for Q2 2011 at Assembly Biosciences, up from $1.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.3 million in Q2 2011 to a low of $1.3 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Assembly Biosciences | 418.96 Mn | 192.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2011 | 1.32 Mn |
| Jun 30, 2011 | 1.32 Mn |
| Dec 31, 2010 | 1.27 Mn |
| Dec 31, 2010 | 1.27 Mn |